Are We Jumping the Gun with Itolizumab in India? A Situational Analysis from the Pre-COVID Era

Itolizumab, an anti-CD6 monoclonal antibody, has been recently approved for the off-label indication of cytokine release syndrome in the background of COVID-19, by the Drug Controller General of India. However, this drug has not been included in the National Clinical Management Protocol for COVID-19...

Descripción completa

Detalles Bibliográficos
Autores principales: Thangaraju, Pugazhenthan, Venkatesan, Nanditha, Thangaraju, Eswaran, Venkatesan, Sajitha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Covid-19
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7519855/
https://www.ncbi.nlm.nih.gov/pubmed/33015549
http://dx.doi.org/10.1007/s42399-020-00550-3
_version_ 1783587656830025728
author Thangaraju, Pugazhenthan
Venkatesan, Nanditha
Thangaraju, Eswaran
Venkatesan, Sajitha
author_facet Thangaraju, Pugazhenthan
Venkatesan, Nanditha
Thangaraju, Eswaran
Venkatesan, Sajitha
author_sort Thangaraju, Pugazhenthan
collection PubMed
description Itolizumab, an anti-CD6 monoclonal antibody, has been recently approved for the off-label indication of cytokine release syndrome in the background of COVID-19, by the Drug Controller General of India. However, this drug has not been included in the National Clinical Management Protocol for COVID-19 yet. The limited-to-no experience of the Indian health workforce with the drug urged us to conduct a situational analysis in the pre-COVID era to analyse the degree of use of the drug and the indications for which it has been employed.
format Online
Article
Text
id pubmed-7519855
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-75198552020-09-28 Are We Jumping the Gun with Itolizumab in India? A Situational Analysis from the Pre-COVID Era Thangaraju, Pugazhenthan Venkatesan, Nanditha Thangaraju, Eswaran Venkatesan, Sajitha SN Compr Clin Med Covid-19 Itolizumab, an anti-CD6 monoclonal antibody, has been recently approved for the off-label indication of cytokine release syndrome in the background of COVID-19, by the Drug Controller General of India. However, this drug has not been included in the National Clinical Management Protocol for COVID-19 yet. The limited-to-no experience of the Indian health workforce with the drug urged us to conduct a situational analysis in the pre-COVID era to analyse the degree of use of the drug and the indications for which it has been employed. Springer International Publishing 2020-09-26 2020 /pmc/articles/PMC7519855/ /pubmed/33015549 http://dx.doi.org/10.1007/s42399-020-00550-3 Text en © Springer Nature Switzerland AG 2020 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Covid-19
Thangaraju, Pugazhenthan
Venkatesan, Nanditha
Thangaraju, Eswaran
Venkatesan, Sajitha
Are We Jumping the Gun with Itolizumab in India? A Situational Analysis from the Pre-COVID Era
title Are We Jumping the Gun with Itolizumab in India? A Situational Analysis from the Pre-COVID Era
title_full Are We Jumping the Gun with Itolizumab in India? A Situational Analysis from the Pre-COVID Era
title_fullStr Are We Jumping the Gun with Itolizumab in India? A Situational Analysis from the Pre-COVID Era
title_full_unstemmed Are We Jumping the Gun with Itolizumab in India? A Situational Analysis from the Pre-COVID Era
title_short Are We Jumping the Gun with Itolizumab in India? A Situational Analysis from the Pre-COVID Era
title_sort are we jumping the gun with itolizumab in india? a situational analysis from the pre-covid era
topic Covid-19
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7519855/
https://www.ncbi.nlm.nih.gov/pubmed/33015549
http://dx.doi.org/10.1007/s42399-020-00550-3
work_keys_str_mv AT thangarajupugazhenthan arewejumpingthegunwithitolizumabinindiaasituationalanalysisfromtheprecovidera
AT venkatesannanditha arewejumpingthegunwithitolizumabinindiaasituationalanalysisfromtheprecovidera
AT thangarajueswaran arewejumpingthegunwithitolizumabinindiaasituationalanalysisfromtheprecovidera
AT venkatesansajitha arewejumpingthegunwithitolizumabinindiaasituationalanalysisfromtheprecovidera

Ejemplares similares